||WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
||Plerixafor, a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
||AMD 3100 octahydrochloride
||AMD 3100 octahydrochloride blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bo
||SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
||UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
||SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
||Arteether is a new, fast-acting antimalarial drug.
||Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
||MSX-127 elicites positive response in peptide CXCR4.
||MSX-130 is CXCR4 Antagonist.
||Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxi
||ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of
||MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).
||Danirixin is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
||LIT-927 is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
||Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, cha
||JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).